A research overview of the CJC-1295 ipamorelin blend: the GHRH-plus-GHRP synergy evidence, why the no-DAC form is the conventional partner, and where the human data actually stops.
The CJC-1295 + ipamorelin blend is the most common paired-peptide preparation in the growth-hormone-secretagogue category, and the pairing is not arbitrary. It puts a GHRH analogue and a ghrelin-receptor agonist in the same vial because the two act on different pituitary receptors, and because the combination of those two receptor classes is one of the better-characterized synergies in human endocrine pharmacology. What is not well characterized is this specific blend: there are no published human trials of CJC-1295 plus ipamorelin administered together. The rationale is mechanistic and component-level, and it should be read that way.
Somatotrophs in the anterior pituitary release growth hormone under two opposing upstream controls: GHRH from the hypothalamus drives release, somatostatin restrains it. Ghrelin-receptor (GHS-R1a) agonists act on a third, separate axis — they amplify GHRH-driven release and appear to blunt somatostatin tone.
CJC-1295 is a tetrasubstituted analogue of GHRH(1–29), modified at four positions to resist dipeptidyl peptidase-IV cleavage. Ipamorelin is a pentapeptide GHS-R1a agonist. Stimulating both receptors at once removes the brake and presses the accelerator in the same window, which is why the combined GH response is larger than either agent produces alone.
The synergy claim traces to a well-replicated body of work on GHRH plus GHRPs generally — not to CJC-1295 and ipamorelin specifically.
That is a real, reproducible pharmacological finding. Extending it to this blend requires two assumptions: that ipamorelin behaves like the GHRPs used in those studies at the GHS-R1a receptor (reasonable — it is a selective agonist at the same target), and that CJC-1295 behaves like the GHRH used in those studies at the GHRH receptor (also reasonable). Both assumptions are defensible. Neither has been tested head-to-head in a published combination trial. Anyone claiming a specific percentage of "extra GH" from the blend is extrapolating past the data.
CJC-1295 exists in two pharmacologically different forms, and the distinction changes the entire profile of a blend.
With DAC (drug affinity complex) the peptide binds covalently to serum albumin. Teichman et al. (JCEM, 2006) ran two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults and reported an estimated half-life of 5.8–8.1 days, with mean GH elevated 2- to 10-fold for six days or more and IGF-I elevated 1.5- to 3-fold for nine to eleven days after a single injection. That is a sustained elevation, not a pulse.
Without DAC — also sold as modified GRF(1–29) or mod GRF 1-29 — the molecule clears in roughly half an hour. It produces a discrete pulse rather than a plateau, which is what makes it the conventional partner for a short-acting GHRP. Note that the no-DAC form does not have an equivalent published human pharmacokinetic trial; the short half-life is widely reported but not backed by a paper of the Teichman standard.
Blends are generally formulated with the no-DAC form, because pairing a sharp GHS-R1a pulse with a multi-day GHRH plateau defeats the point of pulsatility. Confirm which form a given vial contains against the label and Certificate of Analysis rather than assuming — see CJC-1295, with DAC or without for the full comparison.
Raun et al. (European Journal of Endocrinology, 1998) introduced ipamorelin as the first selective GH secretagogue. The finding that earned the label: ipamorelin did not raise ACTH or cortisol above what GHRH alone produced, and that held even at doses more than 200-fold above the ED50 for GH release. FSH, LH, prolactin and TSH were likewise unaffected. GHRP-6 and GHRP-2, tested alongside, both raised ACTH and cortisol.
Human pharmacokinetics come from Gobburu et al. (Pharmaceutical Research, 1999) — forty healthy male volunteers, five intravenous dose levels, dose-proportional kinetics, terminal half-life about two hours, and a single GH episode peaking near 40 minutes then declining exponentially.
Ipamorelin is not an approved drug. Its furthest clinical development was a phase 2 program in postoperative ileus, which did not meet its primary endpoint; development was discontinued and it never reached phase 3.
Honest framing: two compounds with individually solid receptor-level characterization and thin-to-moderate human outcome data, combined on a mechanistic rationale that is strong in the abstract and untested in the specific. CJC-1295 has one good published human PK study — of the DAC form. Ipamorelin has one good published human PK/PD study and a failed phase 2. Neither has long-term human safety data. The GH/IGF-I axis is not a system where "more" is self-evidently better, and sustained IGF-I elevation carries its own open questions.
For the component-by-component contrast, see Ipamorelin vs CJC-1295 and the Ipamorelin research overview; for the wider category, growth-hormone secretagogues explained.
Pre-mixed vials also carry a practical constraint worth naming: the ratio is fixed at manufacture. Separate vials of CJC-1295 and ipamorelin allow the two variables to move independently; the pre-mixed blend trades that flexibility for a single reconstitution step. Reconstitution volume and concentration math are covered in reconstitution 101 and dosing math.
Is there a published human trial of the CJC-1295 and ipamorelin combination? No. No peer-reviewed randomized trial of the two administered together has been published. The synergy rationale rests on studies of GHRH combined with GHRPs as receptor classes, most notably Bowers et al. (1990), plus separate component-level data on each compound.
Why is the no-DAC form used in blends? Because the pairing is built around a pulse. The DAC form elevates GH and IGF-I for days after a single injection, which does not combine meaningfully with ipamorelin's roughly two-hour half-life and single ~40-minute GH peak. The no-DAC form clears fast enough for the two signals to overlap in one window.
What makes ipamorelin "selective"? In Raun et al. (1998), ipamorelin released GH without raising ACTH, cortisol, prolactin, FSH, LH or TSH — even at doses far above its GH ED50. GHRP-6 and GHRP-2 raised ACTH and cortisol in the same comparisons. Selectivity here means selectivity for GH over other pituitary and adrenal outputs.
Is either compound approved for any use? Neither is an approved drug. CJC-1295 completed early-phase human studies but was not developed to approval. Ipamorelin's phase 2 postoperative-ileus program missed its primary endpoint and was discontinued.
Does a blend cost less or work better than separate vials? A blend removes one reconstitution step and fixes the component ratio at manufacture. It does not change the underlying pharmacology of either molecule, and no published data compares blended versus separately prepared administration.
